

Magle PharmaCept Partners with Pancreatic Cancer Europe PCE to Advance Innovation in Pancreatic Cancer Care

Magle PharmaCept, a part of Magle Group, announces a strategic partnership with Pancreatic Cancer Europe (PCE), Pancreatic Cancer Europe is a European multi-stakeholder platform which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups and journalists with a common interest and willingness to improve care for patients with pancreatic cancer.

As part of this collaboration, Magle PharmaCept will contribute to the **Treatment Opportunities for Pancreatic Cancer** project, running from 2025 to 2026. The initiative is designed to improve patient outcomes by expanding access to treatment solutions and enhancing surgical care within the pancreatic cancer community. The scope of this work stream aims to present innovations in treatment and to communicate best practices and essential requirements for the quality of patient care. The activities are addressed to patients, patient carers, patient advocates, healthcare staff, and other stakeholders.

"Pancreatic Cancer Europe (PCE) is honoured to begin this new collaboration with Magle for the benefit of pancreatic cancer patients and their families. Magle supports PCE's activities that aim to increase patients' awareness on pancreatic cancer, to enhance their quality of life. I hope that this important partnership will grow over time". Said Maria Luisa Pagano, PCE Secretariat Coordinator.

This joint effort underscores Magle PharmaCept's commitment to bringing life-changing innovation for patients. At Magle PharmaCept, patients come first—we provide advanced medical solutions that transform lives and contribute to the progress of global healthcare through targeted partnerships and innovation.

"This partnership with PCE marks a meaningful step in our aspiration to support healthcare professionals and patients navigating modern pancreatic cancer surgery. " said **Helena Ossmer Thedius, Chief Marketing and Innovation Officer at Magle Group.**

Contact Justin

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Magle PharmaCept Partners with Pancreatic Cancer Europe PCE to Advance Innovation in Pancreatic Cancer Care](#)